Staffan Karlsson
Research Subjects
Staffan Karlsson has a total of 109 co-authors. Here are the top co-authors by number of shared publications:
Hans Emtenäs
Early Chemical Development, Pharmaceutical Sciences, Biopharmaceuticals R&D, AstraZeneca Gothenburg, SE-431 83 Mölndal, Sweden
5 shared publicationsCalum Cook
Early Chemical Development, Pharmaceutical Sciences, Biopharmaceuticals R&D, AstraZeneca Macclesfield, Macclesfield SK10 2NA, United Kingdom
3 shared publicationsChristian Löfberg
AstraZeneca Gothenburg, Cardiovasc Renal & Metab IMED Biotech Unit, Pepparedsleden 1, S-43183 Molndal, Sweden
3 shared publications- Per-Ola Norrby
Predictive Science, Digital and Automation, Pharmaceutical Sciences, R&D AstraZeneca, Pepparedsleden 1, 43183 Mölndal, Sweden
3 shared publications - Subhash Pithani
Early Chemical Development, Pharmaceutical Sciences, AstraZeneca R&D, Mölndal, Gothenburg SE-431 83, Sweden
3 shared publications Andrew D. Campbell
Chemical Development, Pharmaceutical Technology & Development, Operations, AstraZeneca Macclesfield, Macclesfield SK10 2NA, United Kingdom
2 shared publications
Latest Publications
- Open Access
- 17 September 2026
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 30 (10) , 2867-2873
The Batch Nature of Continuous Flow Production via Natural-Abundance Stable Isotopes
By definition, continuous flow (CF) production implies continuity in the products; however, virtually all CF products are derived from batched reactants. Consequently, virtually all aliquots of CF production should retain certain batch characteristics.Roncone, A.; et al. ( Trends Analyt. Chem.2024, 174, 117666., and references therein) demonstrated the highly specific nature of natural-abundance stable isotopes in individual batches of pharmaceutical and chemical materials. Here, we employ elemental analysis/isotope-ratio mass spectrometry (EA-IRMS) to quantify the natural-abundance stable-isotopic variations in CF production of products. We show that the batch nature of the reactants (6-bromonaphth-2-ol and methyl iodide) is transmitted to the product (6-bromonaphth-2-yl methyl ether). Instead of maintaining a smooth, continuous isotopic composition during CF production, the episodically batch-varying isotopic values (δ13C, δD, δ18O) of the reactant batches are transmitted downstream to the products. Although the batch nature of CF production is evident, only an initial evaluation of using isotope effects to parametrize yield (via fraction remaining of the starting material) is possible with the present relatively narrow range of yields. These early observations open new areas for process research. Beyond demonstrating the batch nature of CF production, there are at least two additional utilities in measuring isotopic compositions during CF production: (i) product authentication (batch/aliquot auditing) and (ii) process understanding (monitoring the continuity of the continuous flow reaction).
- 17 September 2026
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 30 (10) , 2867-2873
Open AccessThe Batch Nature of Continuous Flow Production via Natural-Abundance Stable Isotopes
By definition, continuous flow (CF) production implies continuity in the products; however, virtually all CF products are derived from batched reactants. Consequently, virtually all aliquots of CF production should retain certain batch characteristics.Roncone, A.; et al. ( Trends Analyt. Chem.2024, 174, 117666., and references therein) demonstrated the highly specific nature of natural-abundance stable isotopes in individual batches of pharmaceutical and chemical materials. Here, we employ elemental analysis/isotope-ratio mass spectrometry (EA-IRMS) to quantify the natural-abundance stable-isotopic variations in CF production of products. We show that the batch nature of the reactants (6-bromonaphth-2-ol and methyl iodide) is transmitted to the product (6-bromonaphth-2-yl methyl ether). Instead of maintaining a smooth, continuous isotopic composition during CF production, the episodically batch-varying isotopic values (δ13C, δD, δ18O) of the reactant batches are transmitted downstream to the products. Although the batch nature of CF production is evident, only an initial evaluation of using isotope effects to parametrize yield (via fraction remaining of the starting material) is possible with the present relatively narrow range of yields. These early observations open new areas for process research. Beyond demonstrating the batch nature of CF production, there are at least two additional utilities in measuring isotopic compositions during CF production: (i) product authentication (batch/aliquot auditing) and (ii) process understanding (monitoring the continuity of the continuous flow reaction).
- Open Access
- 25 June 2026
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 30 (7) , 1987-1995
Optimization of a Resolution Process Allowing Access to Both Enantiomers of the Versatile Chiral Phosphine Ligand sSPhos on Scale
Broadly effective, chiral monodentate phosphine ligands in asymmetric catalysis are relatively rare. sSPhos is a versatile, axially chiral phosphine that is capable of inducing high levels of enantioselectivity in a number of palladium-catalyzed transformations, including atroposelective Suzuki-Miyaura cross-coupling, arylative dearomatization, and carboetherification reactions. We have previously reported the chiral resolution of sSPhos by salt formation with quinidine, permitting the isolation of the (R) enantiomer. That process possessed several limitations, including relatively small scale, inability to access the (S) enantiomer, the requirement to presynthesize a trifluoroacetate salt of the dihydroquinine, and a maximum ee of 98% of (R)-sSPhos. In this work, we report further optimization and development of that procedure to permit it to be performed on a large scale. This simplified process permits the protonated, zwitterionic form of (R)-sSPhos to be obtained in >99% ee and (S)-sSPhos in 98% ee. The new modified procedure includes a resolution of racemic sSPhos by crystallization and was demonstrated on an 80 g scale to give access to both enantiomers of sSPhos in high ee and good yield. It is notable that the (S)-sSPhos enantiomer had previously been available only through preparative separation. We anticipate that this will assist in the incorporation of sSPhos as a chiral ligand in screening libraries and facilitate industrial application.
- 25 June 2026
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 30 (7) , 1987-1995
Open AccessOptimization of a Resolution Process Allowing Access to Both Enantiomers of the Versatile Chiral Phosphine Ligand sSPhos on Scale
Broadly effective, chiral monodentate phosphine ligands in asymmetric catalysis are relatively rare. sSPhos is a versatile, axially chiral phosphine that is capable of inducing high levels of enantioselectivity in a number of palladium-catalyzed transformations, including atroposelective Suzuki-Miyaura cross-coupling, arylative dearomatization, and carboetherification reactions. We have previously reported the chiral resolution of sSPhos by salt formation with quinidine, permitting the isolation of the (R) enantiomer. That process possessed several limitations, including relatively small scale, inability to access the (S) enantiomer, the requirement to presynthesize a trifluoroacetate salt of the dihydroquinine, and a maximum ee of 98% of (R)-sSPhos. In this work, we report further optimization and development of that procedure to permit it to be performed on a large scale. This simplified process permits the protonated, zwitterionic form of (R)-sSPhos to be obtained in >99% ee and (S)-sSPhos in 98% ee. The new modified procedure includes a resolution of racemic sSPhos by crystallization and was demonstrated on an 80 g scale to give access to both enantiomers of sSPhos in high ee and good yield. It is notable that the (S)-sSPhos enantiomer had previously been available only through preparative separation. We anticipate that this will assist in the incorporation of sSPhos as a chiral ligand in screening libraries and facilitate industrial application.
- 6 February 2026
- Published by Royal Society of Chemistry (RSC) in Reaction Chemistry & Engineering
- Vol. 11 (2) , 359-366
On the automated determination of p K a by NMR in DMSO : water mixtures
We present an automated method to determine p K a values in semi-aqueous solvents via solvent suppressed flow NMR. This technique also allows the site associated with each p K a to be ascertained.
- 6 February 2026
- Published by Royal Society of Chemistry (RSC) in Reaction Chemistry & Engineering
- Vol. 11 (2) , 359-366
On the automated determination of p K a by NMR in DMSO : water mixtures
We present an automated method to determine p K a values in semi-aqueous solvents via solvent suppressed flow NMR. This technique also allows the site associated with each p K a to be ascertained.
- 15 April 2025
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 29 (5) , 1248-1263
Access to Phenolic Pyridopyridazinones and Phthalazinones Using THP Ether-Directed Ortho Lithiation
- 15 April 2025
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 29 (5) , 1248-1263
Access to Phenolic Pyridopyridazinones and Phthalazinones Using THP Ether-Directed Ortho Lithiation
- Open Access
- 28 February 2025
- Published by Royal Society of Chemistry (RSC) in Green Chemistry
- Vol. 27 (12) , 3186-3196
Recovery and reuse of homogeneous palladium catalysts via organic solvent nanofiltration: application in the synthesis of AZD4625
Using OSN, a homogeneous Pd catalyst in AZD4625 synthesis is separated and reused for five cycles, maintaining over 90% conversion.
- 28 February 2025
- Published by Royal Society of Chemistry (RSC) in Green Chemistry
- Vol. 27 (12) , 3186-3196
Open AccessRecovery and reuse of homogeneous palladium catalysts via organic solvent nanofiltration: application in the synthesis of AZD4625
Using OSN, a homogeneous Pd catalyst in AZD4625 synthesis is separated and reused for five cycles, maintaining over 90% conversion.
- Open Access
- 25 February 2025
- Published by American Chemical Society (ACS) in The Journal of Organic Chemistry
- Vol. 90 (10) , 3544-3556
Mechanistic Study of Photochemical Aminocarbonylation of Alkyl Iodides Catalyzed by a Palladium Catalyst Using Experimental and Computational Methods
Aminocarbonylations are versatile reactions amenable to applications in convergent synthesis and isotope labeling. Herein, a mechanistic study of a previously reported visible-light-promoted aminocarbonylation of unactivated alkyl iodides is presented. This study combines in situ spectroscopy, computational chemistry, and organic chemistry techniques. A T1 excited-state promoted ligand dissociation in concert with an atom transfer radical addition was uncovered as a likely first step in the mechanism, instead of the usual three-center oxidative addition. Improvement in the reaction yield was achieved by optimizing the reaction based on mechanistic insights. This took the form of promoting a computationally uncovered cationic carbonylation pathway with the use of bidentate ligands.
- 25 February 2025
- Published by American Chemical Society (ACS) in The Journal of Organic Chemistry
- Vol. 90 (10) , 3544-3556
Open AccessMechanistic Study of Photochemical Aminocarbonylation of Alkyl Iodides Catalyzed by a Palladium Catalyst Using Experimental and Computational Methods
Aminocarbonylations are versatile reactions amenable to applications in convergent synthesis and isotope labeling. Herein, a mechanistic study of a previously reported visible-light-promoted aminocarbonylation of unactivated alkyl iodides is presented. This study combines in situ spectroscopy, computational chemistry, and organic chemistry techniques. A T1 excited-state promoted ligand dissociation in concert with an atom transfer radical addition was uncovered as a likely first step in the mechanism, instead of the usual three-center oxidative addition. Improvement in the reaction yield was achieved by optimizing the reaction based on mechanistic insights. This took the form of promoting a computationally uncovered cationic carbonylation pathway with the use of bidentate ligands.
- 25 April 2024
- Published by American Chemical Society (ACS) in Organic Letters
- Vol. 26 (18) , 3972-3976
Mild Strategy for the Preparation of Alkyl Sulfonyl Fluorides from Alkyl Bromides and Alcohols Using Photoredox Catalysis and Flow Chemistry
Facile access to sp3-rich scaffolds containing a sulfonyl fluoride group is still limited. Herein, we describe a mild and scalable strategy for the preparation of alkyl sulfonyl fluorides from readily available alkyl bromides and alcohols using photoredox catalysis. This approach is based on halogen atom transfer (XAT), followed by SO2 capture and fluorination. The method features mild conditions enabling fast access to high-value derivatives and has been scaled up to 5 g using a continuous stirred tank reactor cascade.
- 25 April 2024
- Published by American Chemical Society (ACS) in Organic Letters
- Vol. 26 (18) , 3972-3976
Mild Strategy for the Preparation of Alkyl Sulfonyl Fluorides from Alkyl Bromides and Alcohols Using Photoredox Catalysis and Flow Chemistry
Facile access to sp3-rich scaffolds containing a sulfonyl fluoride group is still limited. Herein, we describe a mild and scalable strategy for the preparation of alkyl sulfonyl fluorides from readily available alkyl bromides and alcohols using photoredox catalysis. This approach is based on halogen atom transfer (XAT), followed by SO2 capture and fluorination. The method features mild conditions enabling fast access to high-value derivatives and has been scaled up to 5 g using a continuous stirred tank reactor cascade.
- Top Cited PapersOpen Access
- 22 March 2024
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 28 (4) , 891-923
Organic Solvent Nanofiltration in Pharmaceutical Applications
Separation and purification in organic solvents are indispensable procedures in pharmaceutical manufacturing. However, they still heavily rely on the conventional separation technologies of distillation and chromatography, resulting in high energy and massive solvent consumption. As an alternative, organic solvent nanofiltration (OSN) offers the benefits of low energy consumption, low solid waste generation, and easy scale-up and incorporation into continuous processes. Thus, there is a growing interest in employing membrane technology in the pharmaceutical area to improve process sustainability and energy efficiency. This Review comprehensively summarizes the recent progress (especially the last 10 years) of organic solvent nanofiltration and its applications in the pharmaceutical industry, including the concentration and purification of active pharmaceutical ingredients, homogeneous catalyst recovery, solvent exchange and recovery, and OSN-assisted peptide/oligonucleotide synthesis. Furthermore, the challenges and future perspectives of membrane technology in pharmaceutical applications are discussed in detail.
- 22 March 2024
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 28 (4) , 891-923
Top Cited PapersOpen AccessOrganic Solvent Nanofiltration in Pharmaceutical Applications
Separation and purification in organic solvents are indispensable procedures in pharmaceutical manufacturing. However, they still heavily rely on the conventional separation technologies of distillation and chromatography, resulting in high energy and massive solvent consumption. As an alternative, organic solvent nanofiltration (OSN) offers the benefits of low energy consumption, low solid waste generation, and easy scale-up and incorporation into continuous processes. Thus, there is a growing interest in employing membrane technology in the pharmaceutical area to improve process sustainability and energy efficiency. This Review comprehensively summarizes the recent progress (especially the last 10 years) of organic solvent nanofiltration and its applications in the pharmaceutical industry, including the concentration and purification of active pharmaceutical ingredients, homogeneous catalyst recovery, solvent exchange and recovery, and OSN-assisted peptide/oligonucleotide synthesis. Furthermore, the challenges and future perspectives of membrane technology in pharmaceutical applications are discussed in detail.
- 4 October 2022
- Published by American Chemical Society (ACS) in Accounts of Chemical Research
- Vol. 55 (20) , 2938-2948
Approaches to Synthesis and Isolation of Enantiomerically Pure Biologically Active Atropisomers
Atropisomerism is a stereochemical phenomenon exhibited by molecules containing a rotationally restricted σ bond. Contrary to classical point chirality, the two atropisomeric stereoisomers exist as a dynamic mixture and can be interconverted without the requirement of breaking and reforming a bond. Although this feature increases structural complexity, atropisomers have become frequent targets in medicinal chemistry projects. Their axial chirality, e.g., from axially chiral biaryl motifs, gives access to unique 3D structures. It is often desirable to have access to both enantiomers of the atropisomers via a nonselective reaction during the early discovery phase as it allows the medicinal chemistry team to probe the structure activity relationship in both directions. However, once a single atropisomer is selected, it presents several problems. First, the pure single atropisomer may interconvert to the undesired stereoisomer under certain conditions. Second, separation of atropisomers is nontrivial and often requires expensive chiral stationary phases using chromatography or additives if a salt resolution approach is chosen. Other options can be kinetic resolution using enzymes or chiral catalysts. However, apart from the high cost often associated with the two latter methods, a maximum yield of only 50% of the desired atropisomer can be obtained. The ideal approach is to install the chiral atropisomeric axis enantioselectively or employing a dynamic kinetic resolution approach. In theory, both approaches have the potential to provide a single atropisomer in quantitative yield. This Account will discuss the successes/failures and challenges we have experienced in developing methods for resolution/separation and asymmetric synthesis of atropisomeric drug candidates in one of our early phase drug development projects. Suitability for the different methods at various stages of the drug development phase is discussed. Depending on the scale and time available, a separation of a mixture of atropisomers by chromatography was sometimes preferred, whereas asymmetric- or resolution approaches were desired for long-term supply. With the use of chromatography, the impact on separation efficiency and solvent consumption, depending on the nature of the substrate, is discussed. We hope that with this Account the readers will get a better view on the challenges medicinal and process chemists meet when designing new atropisomeric drug candidates and developing processes for manufacture of a single atropisomer.
- 4 October 2022
- Published by American Chemical Society (ACS) in Accounts of Chemical Research
- Vol. 55 (20) , 2938-2948
Approaches to Synthesis and Isolation of Enantiomerically Pure Biologically Active Atropisomers
Atropisomerism is a stereochemical phenomenon exhibited by molecules containing a rotationally restricted σ bond. Contrary to classical point chirality, the two atropisomeric stereoisomers exist as a dynamic mixture and can be interconverted without the requirement of breaking and reforming a bond. Although this feature increases structural complexity, atropisomers have become frequent targets in medicinal chemistry projects. Their axial chirality, e.g., from axially chiral biaryl motifs, gives access to unique 3D structures. It is often desirable to have access to both enantiomers of the atropisomers via a nonselective reaction during the early discovery phase as it allows the medicinal chemistry team to probe the structure activity relationship in both directions. However, once a single atropisomer is selected, it presents several problems. First, the pure single atropisomer may interconvert to the undesired stereoisomer under certain conditions. Second, separation of atropisomers is nontrivial and often requires expensive chiral stationary phases using chromatography or additives if a salt resolution approach is chosen. Other options can be kinetic resolution using enzymes or chiral catalysts. However, apart from the high cost often associated with the two latter methods, a maximum yield of only 50% of the desired atropisomer can be obtained. The ideal approach is to install the chiral atropisomeric axis enantioselectively or employing a dynamic kinetic resolution approach. In theory, both approaches have the potential to provide a single atropisomer in quantitative yield. This Account will discuss the successes/failures and challenges we have experienced in developing methods for resolution/separation and asymmetric synthesis of atropisomeric drug candidates in one of our early phase drug development projects. Suitability for the different methods at various stages of the drug development phase is discussed. Depending on the scale and time available, a separation of a mixture of atropisomers by chromatography was sometimes preferred, whereas asymmetric- or resolution approaches were desired for long-term supply. With the use of chromatography, the impact on separation efficiency and solvent consumption, depending on the nature of the substrate, is discussed. We hope that with this Account the readers will get a better view on the challenges medicinal and process chemists meet when designing new atropisomeric drug candidates and developing processes for manufacture of a single atropisomer.
- 1 March 2022
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 26 (4) , 1048-1053
Using Oxygen as the Primary Oxidant in a Continuous Process: Application to the Development of an Efficient Route to AZD4635
- 1 March 2022
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 26 (4) , 1048-1053
Using Oxygen as the Primary Oxidant in a Continuous Process: Application to the Development of an Efficient Route to AZD4635